Showing results (11-20 of 108) with videos related to

Sort By:
Pageof 11
Chemical Communications (Cambridge, England)|October 7, 2016
A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodiesStacey E Rudd, Peter Roselt, Carleen Cullinane, et al.
Chemical Communications (Cambridge, England)|October 7, 2016
Correction: A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodiesStacey E Rudd, Peter Roselt, Carleen Cullinane, et al.
Plos One|February 25, 2011
RNAi-mediated knock-down of arylamine N-acetyltransferase-1 expression induces E-cadherin up-regulation and cell-cell contact growth inhibitionJacky M Tiang, Neville J Butcher, Carleen Cullinane, et al.
Chemical Science|February 3, 2025
Potential theranostics of breast cancer with copper-64/67 sarcophagine-trastuzumabStacey E Rudd, Jessica Van Zuylekom, Carleen Cullinane, et al.
International Journal of Radiation Oncology, Biology, Physics|February 8, 2003
EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptorBenjamin Solomon, Jim Hagekyriakou, Melanie K Trivett, et al.
EJNMMI Research|October 11, 2015
Rapid kit-based (68)Ga-labelling and PET imaging with THP-Tyr(3)-octreotate: a preliminary comparison with DOTA-Tyr(3)-octreotateMichelle T Ma, Carleen Cullinane, Kelly Waldeck, et al.
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|August 21, 2007
Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET resultsGerald Reischl, Donna S Dorow, Carleen Cullinane, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|December 16, 2006
Studies of a cobalt(III) complex of the MMP inhibitor marimastat: a potential hypoxia-activated prodrugTimothy W Failes, Carleen Cullinane, Connie I Diakos, et al.
Scientific Reports|June 25, 2020
Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARPCarleen Cullinane, Kelly Waldeck, Laura Kirby, et al.
Molecular Cancer Therapeutics|September 20, 2005
Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imagingBenjamin Solomon, David Binns, Peter Roselt, et al.
Pageof 11